Compounded Sema Injectable denied as non-formulary by Cigna?

Cigna's specific coverage criteria for compounded sema injectable are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Compounded Semaglutide as Non-Formulary

Cigna's formulary — its approved drug list — covers FDA-approved finished pharmaceutical products. Compounded semaglutide, prepared by a compounding pharmacy, is not an FDA-approved finished drug product and therefore does not appear on Cigna's formulary. A non-formulary denial is thus essentially certain for any compounded medication: the product, by its nature, was never submitted for formulary placement. This makes the non-formulary denial for compounded semaglutide both predictable and one of the most common reasons patients contact us for help.

## Why This Is Appealable

Even when a drug is non-formulary, most Cigna plans have a formal exceptions process that allows coverage when a formulary alternative is not clinically appropriate for a specific patient. The appeal is filed as a formulary exception request and must demonstrate one of the following: the formulary alternatives (the FDA-approved branded semaglutide products) are not accessible due to a documented shortage; the patient tried a formulary alternative and it was not tolerable or effective; or the patient has a documented clinical reason that makes the formulary alternatives contraindicated or impractical. The strength of the exception request depends almost entirely on the quality of the documentation.

## The Federal Appeal Framework

• Formulary exception / internal appeal: File the exception request and internal appeal simultaneously under ERISA Section 503 or ACA Section 2719 within the deadline in the denial notice. Cigna must respond to pre-service exceptions within 72 hours (or 24 hours for urgent requests).
• External review: After the internal exception/appeal process is exhausted, request independent external review under ACA Section 2719 within approximately four months of the final denial. External reviewers assess medical necessity using clinical standards, which can override formulary determinations.
• Expedited option: If delay poses immediate clinical risk, request expedited review explicitly in writing.

## Documentation to Gather

• Formulary alternative access barrier: Documentation of the FDA drug shortage database entry for the branded semaglutide product at the time of prescribing, or a formulary review showing the branded product is excluded or has prohibitive cost-sharing under this specific plan.
• Prior formulary alternative history: If the patient tried a formulary GLP-1 agent, complete records of that trial — dates, outcomes, documented reason for discontinuation.
• Clinical contraindication (if applicable): Prescriber documentation of a specific clinical reason the branded formulation is not appropriate for this patient.
• Diagnosis and severity documentation: Chart records confirming the underlying diagnosis, its clinical severity, and the overall treatment history.
• Prescriber medical-necessity letter: A letter directly addressing the non-formulary exception criteria in Cigna's plan documents, explaining why no formulary alternative is clinically appropriate or accessible.

## Criteria-Mapping Structure

Review the formulary exception criteria in your Cigna plan's Summary of Benefits and Coverage (SBC) and the plan's evidence of coverage document:

| Formulary Exception Criterion | Supporting Documentation | |---|---| | Formulary alternative not appropriate | Prior trial records with outcomes, or contraindication note | | Formulary alternative not accessible | FDA shortage documentation or formulary cost-sharing barrier | | Drug is medically necessary for this patient | Prescriber letter with diagnosis, severity, and treatment history |

Also confirm whether your specific Cigna plan is a self-funded employer plan (governed by ERISA) or a fully insured plan — this affects which state laws and appeal rights may supplement your federal rights.